Table 2 Characteristics of the patients treated with nivolumab.

Tumour type

 MM

24

22

2

0.103

 NSCLC

54

50

4

 RCC

21

18

3

 HN

28

24

4

 GC

19

17

2

 HL

1

0

1

Sex

 Male

104

94

10

0.767

 Female

43

38

5

Age, years (range)

64 ± 12

64 ± 12

63 ± 11

1.000

(28–86)

(28–86)

(40–78)

Follow-up period (days)

346 ± 261

340 ± 262

392 ± 255

0.473

History of prior immunotherapy

10

9

1

1.000

Positive for anti-thyroid antibodies at baseline

26

15

11

< 0.001